脑膜炎双球菌疫苗市场规模、份额及成长分析（按类型、最终用户和地区划分）－2026年至2033年产业预测

预计到 2024 年，脑膜炎双球菌疫苗市值将达到 37.1 亿美元，到 2025 年将成长至 39.4 亿美元，到 2033 年将成长至 63.3 亿美元，在预测期（2026-2033 年）内复合年增长率为 6.1%。

由于全球脑膜炎发生率不断上升，脑膜炎双球菌疫苗市场预计将迎来显着成长。据估计，全球每年约有120万例细菌性脑膜炎病例报告。疫苗接种活动的加强和公众对该疾病的认识进一步推动了市场扩张。各国脑膜炎协会等重要的政府和非政府组织在研发和製定新的预防策略方面发挥关键作用。目前市售的脑膜炎双球菌疫苗涵盖多种菌株，包括A、B、C、W-135和Y型，并提供单价和多价疫苗两种选择。此外，将这些疫苗纳入国家免疫规划的趋势以及疫苗技术的进步预计将推动市场成长，但严格的监管准则可能会带来挑战。

推动脑膜炎双球菌疫苗市场发展的因素

脑膜炎球菌疫苗市场的主要驱动力是全球脑膜炎球菌病菌感染的不断增加。由脑膜炎奈瑟菌引起的脑膜炎和败血症死亡率高，并可能导致严重的长期併发症，包括神经损伤。因此，医疗机构强调透过接种疫苗进行预防的重要性。撒哈拉以南非洲地区，即所谓的“脑膜炎带”，尤其容易受到这些感染疾病。人们对脑膜炎球菌感染日益增长的认识以及对有效预防措施的迫切需求，正在推动对脑膜炎球菌疫苗的需求，并促进市场成长。

脑膜炎双球菌疫苗的市场限制

脑膜炎双球菌疫苗市场面临的主要障碍是其生产和分销高成本。脑膜炎球菌病菌感染高发生率的低收入地区难以取得先进疫苗，尤其是采用重组结合技术的疫苗。儘管政府机构和非政府组织提供补贴，但疫苗价格仍然是一个持续存在的挑战，阻碍了疫苗的广泛接种。这种经济障碍不仅影响疫苗的可及性，也为在最需要的人群中实现全面疫苗接种覆盖率带来了挑战。

脑膜炎双球菌疫苗市场趋势

脑膜炎双球菌疫苗市场正呈现出显着的趋势，即采用能够抵御多种菌株的联合疫苗。对涵盖A、C、W和Y群的四价疫苗的需求不断增长，显示人们希望获得更广泛的保护，这有效地简化了疫苗接种程序。这种转变不仅减少了多剂接种带来的后勤挑战，也有助于提高病患的疫苗接种依从性。随着医护人员和患者都认识到全面保护的益处，预计这一趋势将对整体公共卫生产生积极影响，并有助于提高全球疫苗接种策略的效率。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析和影响

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管环境
• 专利分析
• 案例研究

全球脑膜炎双球菌疫苗市场规模（按疫苗类型和复合年增长率划分）（2026-2033 年）

• 多醣体疫苗
• 结合疫苗
  • 四价
  • 二价
  • 单价疫苗
• 联合疫苗
• B型脑膜炎双球菌疫苗

全球脑膜炎双球菌疫苗市场规模（按品牌和复合年增长率划分）（2026-2033 年）

• 梅纳克特拉
• 门贝奥
• 尼门里克斯
• 贝克塞洛
• 真正的会员
• 其他的

全球脑膜炎双球菌疫苗市场规模（依年龄层划分）及复合年增长率（2026-2033 年）

• 婴幼儿
• 儿童
• 青春期
• 成人

全球脑膜炎双球菌疫苗市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 医院
• 诊所
• 疫苗接种中心
• 其他的

全球脑膜炎双球菌疫苗市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 英国
  • 德国
  • 西班牙
  • 法国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2021-2023年营收年比比较

主要企业简介

• Pfizer Inc.
• GlaxoSmithKline plc
• Sanofi SA
• Merck & Co., Inc.
• Novartis AG
• CSL Limited
• Serum Institute of India Pvt. Ltd.
• Biomed Pvt. Ltd.
• Bharat Biotech
• Biological E. Limited
• Hualan Biological Engineering Inc.
• Walvax Biotechnology Co., Ltd.
• Chongqing Zhifei Biological Products Co., Ltd.
• Emergent BioSolutions Inc.
• Incepta Vaccine Ltd.
• Panacea Biotec Ltd.
• LG Chem Ltd.
• Mitsubishi Tanabe Pharma Corporation
• Valneva SE
• Vaxart, Inc.

结论与建议

Meningococcal Vaccines Market size was valued at USD 3.71 Billion in 2024 and is poised to grow from USD 3.94 Billion in 2025 to USD 6.33 Billion by 2033, growing at a CAGR of 6.1% during the forecast period (2026-2033).

The meningococcal vaccines market is poised for significant growth, driven by the rising incidence of meningitis globally, with an estimated 1.2 million cases of bacterial meningitis reported. Increased immunization initiatives and heightened awareness about the disease are further bolstering market expansion. Key government and non-government organizations, such as national meningitis associations, play a crucial role in promoting research and developing new prevention strategies. The available meningococcal vaccines target various strains, including A, B, C, W-135, and Y, with options for both monovalent and multivalent formulations. Moreover, the growing trend towards incorporating these vaccines into national immunization programs and the advancement in vaccine technology are expected to drive market momentum, even as stringent regulatory guidelines may pose challenges.

Top-down and bottom-up approaches were used to estimate and validate the size of the Meningococcal Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Meningococcal Vaccines Market Segments Analysis

Global Meningococcal Vaccines Market is segmented by vaccine type, brand, age group, end user and region. Based on vaccine type, the market is segmented into polysaccharide vaccines, conjugate vaccines (quadrivalent, bivalent, monovalent), combination vaccines and men b vaccines. Based on brand, the market is segmented into menactra, menveo, nimenrix, bexsero, trumenba and others. Based on age group, the market is segmented into infants, children, adolescents and adults. Based on end user, the market is segmented into hospitals, clinics, vaccination centers and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Meningococcal Vaccines Market

The meningococcal vaccines market is significantly propelled by the increasing occurrence of meningococcal diseases worldwide. Conditions like meningitis and septicemia caused by Neisseria meningitis are associated with high mortality rates and can result in serious long-term complications, including neurological damage. Consequently, health care providers are emphasizing the importance of prevention through vaccination. Certain areas, particularly Sub-Saharan Africa, are recognized as "meningitis belts," where the prevalence of these infections is notably high. This rising awareness and the urgent need for effective preventive measures are driving the demand for meningococcal vaccines, thereby expanding the market.

Restraints in the Meningococcal Vaccines Market

A significant obstacle in the meningococcal vaccines market is the elevated costs linked to both production and distribution. The availability of advanced vaccines, particularly those utilizing conjugated recombinant technologies, is limited in low-income regions that experience a high incidence of meningococcal disease. Despite the support from governmental and non-governmental organizations in the form of subsidies, the issue of affordability persists, impeding extensive vaccination initiatives. This financial barrier not only affects access to vaccines but also challenges efforts to achieve comprehensive immunization coverage in populations that need it the most.

Market Trends of the Meningococcal Vaccines Market

The meningococcal vaccines market is witnessing a significant trend towards the adoption of combination vaccines, which offer protection against multiple strains of the bacteria. The growing preference for quadrivalent vaccines that target serogroups A, C, W, and Y highlights a demand for broader coverage, effectively simplifying vaccination regimens. This shift not only alleviates logistical challenges associated with administering multiple doses but also enhances patient compliance with immunization schedules. As healthcare providers and patients alike recognize the benefits of comprehensive protection, the trend is expected to contribute positively to overall public health outcomes and streamline vaccination strategies worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Patent Analysis
• Case Studies

Global Meningococcal Vaccines Market Size by Vaccine Type & CAGR (2026-2033)

• Market Overview
• Polysaccharide Vaccines
• Conjugate Vaccines
  • Quadrivalent
  • Bivalent
  • Monovalent
• Combination Vaccines
• Men B Vaccines

Global Meningococcal Vaccines Market Size by Brand & CAGR (2026-2033)

• Market Overview
• Menactra
• Menveo
• Nimenrix
• Bexsero
• Trumenba
• Others

Global Meningococcal Vaccines Market Size by Age Group & CAGR (2026-2033)

• Market Overview
• Infants
• Children
• Adolescents
• Adults

Global Meningococcal Vaccines Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Vaccination Centers
• Others

Global Meningococcal Vaccines Market Size & CAGR (2026-2033)

• North America (Vaccine Type, Brand, Age Group, End User)
  • US
  • Canada
• Europe (Vaccine Type, Brand, Age Group, End User)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific (Vaccine Type, Brand, Age Group, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America (Vaccine Type, Brand, Age Group, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Vaccine Type, Brand, Age Group, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Serum Institute of India Pvt. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biomed Pvt. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biological E. Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hualan Biological Engineering Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Walvax Biotechnology Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chongqing Zhifei Biological Products Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incepta Vaccine Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Panacea Biotec Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LG Chem Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Tanabe Pharma Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valneva SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vaxart, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation